Skip to main content
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.860
+0.070 (1.85%)
Feb 27, 2026, 4:00 PM EST - Market closed

Iovance Biotherapeutics Revenue

In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth. Iovance Biotherapeutics had revenue of $86.77M in the quarter ending December 31, 2025, with 17.75% growth.

Revenue (ttm)
$263.50M
Revenue Growth
+60.60%
P/S Ratio
6.03
Revenue / Employee
$270,258
Employees
975
Market Cap
1.59B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025263.50M99.43M60.60%
Dec 31, 2024164.07M162.88M13,698.99%
Dec 31, 20231.19M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Novavax 1.12B
Harmony Biosciences Holdings 868.45M
Ardelyx 407.32M
Immunocore Holdings 400.02M
Nurix Therapeutics 83.98M
Intellia Therapeutics 67.67M
Generate Biomedicines 31.89M
Revenue Rankings

IOVA News

More News